A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)

This is a multicenter, randomized, controlled, open-label, phase III clinical study to evaluate the efficacy of Equecabtagene Autoleucel Injection versus standard therapy in subjects with lenalidomid-refractory RRMM who have received 1-2 lines of prior therapy.

Trial Details

NCT ID
NCT06464991
Phase
PHASE3
Sponsor
Nanjing IASO Biotechnology Co., Ltd.
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Equecabtagene Autoleucel Injection
  • Daratumumab
  • Pomalidomide
  • Bortezomib
  • Dexamethasone
Locations (sample)
  • Beijing, China|39.9075,116.39723
  • Beijing, China|39.9075,116.39723
  • Beijing, China|39.9075,116.39723
  • Beijing, China|39.9075,116.39723
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • 18 to 75 years of age (inclusive of critical values), either gender.
  • The subject was previously diagnosed with multiple myeloma and had received 1-2 lines of therapy (including chemotherapy regimens based on proteaso…
  • Subjects was lenalidomide-refractory during prior therapy.
  • ECOG score of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →